Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19
| Autor: | Satoru Chiba |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oseltamivir medicine.medical_specialty China Duration of fever Coronavirus disease 2019 (COVID-19) Levofloxacin 030204 cardiovascular system & hematology Antiviral Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interquartile range Diabetes mellitus Internal medicine Early treatment Influenza Human Outpatients medicine Humans 030212 general & internal medicine Hypoxia business.industry SARS-CoV-2 Onset to treatment Outbreak COVID-19 General Medicine Hypoxia (medical) Middle Aged medicine.disease chemistry Female Original Article medicine.symptom business medicine.drug |
| Zdroj: | Wiener Klinische Wochenschrift Wiener klinische Wochenschrift |
| ISSN: | 1613-7671 |
| Popis: | Summary Background Since December 2019 coronavirus disease 2019 (COVID-19) outbreaks have occurred in China and many countries around the world. The effectiveness of oseltamivir on COVID-19 suspected outpatients without hypoxia was evaluated. Methods A total of 16 COVID-19 suspected medical personnel and their cohabitation families without hypoxia, who came to the adult fever clinic from March to June 2020 were studied. All patients received antiviral therapy (oseltamivir) and antibacterial therapy together. Results Most of the infected patients were female (10, 63%), 1 had diabetes (6%) and 3 hypertension (19%). The median age was 45 years (interquartile range [IQR] 31–60 years). Oseltamivir administration made the temperature fall within 24 h in part (10, 63%). Clinical data were compared between patients receiving early treatment (ET) with oseltamivir, initiated within 24 h, and patients administered late treatment (LT), initiated after this time point. Duration of fever was shorter in the ET group than in the LT group (31 ± 21 h versus 94 ± 38 h; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink